Physician profile
Philip Lackey
NPI 1083690325
$2,198.10
in general payments reported to CMS, 2019-2025
35 companies · $24.29 in 2025
The $24.29 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $533 · 2021: $610 · 2022: $618 · 2023: $67.50 · 2024: $37.48 · 2025: $24.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.22 | 2019-2022 | |
| Abbvie INC. | $215.08 | 2021-2023 | |
| Amgen INC. | $165.78 | 2020-2022 | |
| Amarin Pharma, INC. | $140.60 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.49 | 2020-2022 | |
| Daiichi Sankyo INC. | $118.87 | 2021-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $116.86 | 2019-2021 | |
| Pfizer INC. | $91.20 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $83.77 | 2020-2022 | |
| Insmed, INC. | $75.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $64.01 | 2020-2022 | |
| Abbott Laboratories | $60.16 | 2022-2025 | Eterna |
| Allergan, INC. | $53.92 | 2019-2020 | |
| Lilly USA, LLC | $53.13 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $50.87 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $50.23 | 2022 | |
| Genentech USA, INC. | $41.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $41.38 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.21 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.80 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $30.77 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.92 | 2020-2021 | |
| Esperion Therapeutics, INC. | $22.86 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.49 | 2019 | |
| Mylan Specialty L.P. | $18.38 | 2020 | |
| Medicure Pharma INC. | $17.47 | 2022 | |
| Gilead Sciences, INC. | $17.38 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.01 | 2021 | |
| Mannkind Corporation | $16.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.73 | 2021 | |
| Philips North America LLC | $16.26 | 2020 | |
| Vivus LLC | $15.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2021 | |
| Grt US Holding, INC. | $12.34 | 2021 | |
| Dermira, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Lackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.